Raymond James & Associates »

Protagonist Therapeutics shares owned by Raymond James & Associates

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by Raymond James & Associates from 13F filings

Historical chart of Raymond James & Associates investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by Raymond James & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by Raymond James & Associates

Quarter filed Position value Share count Share price at filing
2024-03-31 $317k 11k 28.93

More positions owned by Raymond James & Associates

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
Amazon (AMZN)
NVIDIA Corporation (NVDA)
Ishares Tr Core Msci Eafe (IEFA)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Alphabet Cap Stk Cl A (GOOGL)
Home Depot (HD)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Msci Usa Min Vol (USMV)
Merck & Co (MRK)
Eaton Corp SHS (ETN)

View all positions for Raymond James & Associates

Top funds holding Protagonist Therapeutics

BVF
Vanguard Group
Point72 Asset Management
Johnson & Johnson
Kynam Capital Management
Cowen And Company
Leucadia National Corporation
Deutsche Bank Aktiengesellschaft
T. Rowe Price Associates
Dimensional Fund Advisors
683 Capital Management
Goldman Sachs Group
Charles Schwab Investment Management
Citadel Advisors
Jpmorgan Chase & Co

View all funds holding Protagonist Therapeutics